Veronique Ligeon

BioMérieux, Lyons, Rhône-Alpes, France

Are you Veronique Ligeon?

Claim your profile

Publications (2)6.03 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-1 RNA plasma level is a key parameter for anti-viral treatment monitoring in HIV-1 infected individuals. Plasma stability and accurate measurement of clinical state is at risk when transporting from remote areas. Dried blood spot (DBS) testing can reduce this risk. Determine the performance of NucliSENS EasyQ HIV-1 v2.0 for DBS. 100 HIV-1 negative, and 129 HIV-1 spiked blood specimens (2180 copies/ml) were used for diagnostic specificity and system robustness. Analytical performance was tested in the range 50-85,000,000 copies/ml. Clinical reactivity was measured with specimens obtained from 224 HIV-1 infected individuals. HIV-1 RNA stability was analyzed after applying several different storage conditions. Diagnostic specificity was 100% and system robustness was demonstrated by 100% detection rate without invalids. Limit of detection (95% detection rate) was 800 copies/ml. Linear results were obtained over the whole range tested. For clinical specimens, percentage positive results were comparable for DBS (57%) and plasma (58%). DBS quantification was on average 0.36log10 lower as compared to plasma. Specimen stability was demonstrated for 1 week at 55 degrees C/60% humidity, 3 weeks at 37 degrees C/80% humidity, 9 weeks at 37 degrees C/40% humidity, 3 months at -20 degrees C/70% humidity, 3 weeks at 4 degrees C/100% humidity, 9 months at room temperature (15-30 degrees C), and 9 weeks shipment simulation. Results obtained fully support the use of DBS for the NucliSENS EasyQ HIV-1 v2.0 assay. These findings are especially of importance in cases that plasma stability is currently at risk due to for example, long transport routes from remote areas under less controlled conditions.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 12/2009; 47(2):120-5. DOI:10.1016/j.jcv.2009.11.021 · 3.02 Impact Factor

  • Journal of Clinical Virology 09/2009; 46. DOI:10.1016/S1386-6532(09)70136-2 · 3.02 Impact Factor